Cyril Amarchand Mangaldas has advised Aragen Life Sciences Limited on its proposed initial public offering. Trilegal advised the book running lead managers (BRLMs) including Axis Capital, Citigroup Global, Goldman Sachs and JM Financial while TT&A acted as the legal counsel for Leo Investment Holdings and Quadria Capital India Fund III (both Quadria affiliate entities) on this transaction.
Aragen Life Sciences Ltd. IPO is a book build issue consisting of fresh issue of INR 800 crores and an offer for sale (OFS) of up to 2.73 crore equity shares by the selling shareholders.
The equity shares are proposed to be listed on NSE and BSE.
The proposed offering will provide Aragen with additional capital to strengthen its balance sheet while supporting investments in its research, development and manufacturing infrastructure.
Aragen Life Sciences is a contract research, development and manufacturing organisation (CRDMO) providing services across the drug development value chain, including solutions for both small molecules and biologics. The company serves global pharmaceutical, biotechnology and other life sciences companies.
CAM’s transaction team was led by senior partner Yash J Ashar, partner Tanvi Kini, with support from senior associate Surya Rajkumar, and associates Tejaswi Sade, Mohammed Khadri, Maria Palamattom and Akshita Dhawan.
Trilegal’s capital markets team advising on the transaction was led by partners Bhakta Patnaik and Albin Thomas and comprised counsel Bhargavi Mahajan and associates Janhavi Shah, Snehal Kaushal, Tushar Chitlangia, Mohak Agarwal, and Harshali Srivastava.
TT&A team consisted of partner Abhinav Kumar and senior associate Indira Satish.
